Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14647162 | 0.93 | GPR183 (0.48) | PARP1ALDH1A1MAPK1MEN1LMNA | |
| SCHEMBL14647155 | 0.92 | — | — | |
| SCHEMBL14647167 | 0.84 | PARP1 (0.65) | PARP1ALDH1A1KDM4E | |
| SCHEMBL14647223 | 0.84 | SIGMAR1 (0.45) | PARP1ALDH1A1LMNATSHRKMT2A | |
| SCHEMBL14647128 | 0.84 | PARP1 (0.51) | PARP1ALDH1A1MEN1LMNATSHR | |
| SCHEMBL14647161 | 0.84 | MGLL (0.52) | PARP1ALDH1A1MAPK1MEN1LMNA | |
| SCHEMBL14647212 | 0.84 | PARP1 (0.61) | PARP1MEN1TSHRKMT2AHPGD | |
| SCHEMBL14647181 | 0.82 | PARP1 (0.56) | PARP1KMT2ASIGMAR1 | |
| SCHEMBL14647149 | 0.80 | MAPT (0.55) | ALDH1A1MAPK1LMNATSHRSMN1; SMN2 | |
| SCHEMBL14647141 | 0.80 | PARP1 (0.45) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2733144-B1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | claimed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | claimed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | claimed |
| EP-2733144-B1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| EP-2733144-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2014-05-21 | — | — | EP | disclosed |
| EP-2733144-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013008872-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | 参天製薬株式会社 (JP) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | PARP1, PARP11, PARP2 | PARP1 1/4885ALDH1A1 532/4885MAPK1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.